TENCENT
00700
TME-SW
01698
XIAOMI-W
01810
ALI HEALTH
00241
KUAISHOU-W
01024
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 6.26%326.02B | 18.07%226.77B | 14.08%111.47B | -1.33%416.61B | -1.39%306.82B | -5.09%192.06B | 7.50%97.71B | 71.56%422.23B | --311.15B | 83.57%202.36B |
Operating income | 6.26%326.02B | 18.07%226.77B | 14.08%111.47B | -1.33%416.61B | -1.39%306.82B | -5.09%192.06B | 7.50%97.71B | 71.56%422.23B | 311.15B | 83.57%202.36B |
Operating expenses | 3.98%-148.5B | -4.61%-51.91B | -9.15%-154.65B | -31.18%-49.63B | -141.69B | |||||
Gross profit | 16.66%177.53B | 23.85%59.55B | -10.20%152.17B | -9.39%48.08B | 169.46B | |||||
Selling expenses | 1.11%-2.59B | -4.63%-5.22B | -1.14%-884M | -4.62%-10.95B | -5.60%-2.62B | -13.98%-4.99B | -13.51%-874M | -16.82%-10.47B | ---2.48B | -13.07%-4.38B |
Administrative expenses | -5.40%-5.03B | ---- | -22.51%-1.62B | ---- | -16.41%-4.78B | ---- | -7.12%-1.32B | ---- | ---4.1B | ---- |
Research and development expenses | -2.78%-1.22B | ---- | 4.27%-336M | ---- | -46.43%-1.19B | ---- | -56.00%-351M | ---- | ---812M | ---- |
Profit from asset sales | 1,350.00%25M | ---- | 50.00%3M | ---- | -114.29%-2M | ---- | -33.33%2M | ---- | --14M | ---- |
Depreciation and amortization | ---- | -11.31%-37.56B | ---- | -9.70%-68.95B | ---- | -14.34%-33.74B | ---- | -9.81%-62.85B | ---- | -2.04%-29.51B |
Revaluation surplus | 102.90%980M | ---- | -89.87%56M | ---- | 222.00%483M | ---- | 1,070.18%553M | ---- | --150M | ---- |
-Changes in the fair value of other assets | 102.90%980M | ---- | -89.87%56M | ---- | 222.00%483M | ---- | 1,070.18%553M | ---- | --150M | ---- |
Impairment and provision | 85.89%-45M | 88.67%-34M | -2,400.00%-25M | -440.09%-3.6B | -184.82%-319M | -191.26%-300M | 66.67%-1M | 91.63%-666M | ---112M | -80.70%-103M |
-Other impairment is provision | 85.89%-45M | 88.67%-34M | -2,400.00%-25M | -440.09%-3.6B | -184.82%-319M | -191.26%-300M | 66.67%-1M | 91.63%-666M | ---112M | -80.70%-103M |
Special items of operating profit | -60.01%1.6B | -12.69%-68.06B | -36.79%615M | -3.58%-141.01B | 1.35%3.99B | 2.72%-60.39B | 666.14%973M | -110.07%-136.14B | --3.94B | -129.43%-62.08B |
Operating profit | 16.36%155.83B | 25.24%105.54B | 20.76%52.29B | -13.22%167.77B | -11.90%133.92B | -13.18%84.27B | -7.16%43.3B | 101.42%193.33B | 152B | 113.57%97.06B |
Financing income | ---- | 12.91%2.6B | ---- | 61.24%4.81B | ---- | 106.28%2.3B | ---- | 122.22%2.98B | ---- | 105.72%1.12B |
Financing cost | -91.67%-1.43B | -18.86%-3.33B | 532.65%310M | 11.17%-5.35B | 65.75%-744M | 9.82%-2.8B | 107.17%49M | -0.13%-6.03B | ---2.17B | -9.41%-3.11B |
Share of profits of associates | ---- | -4.96%402M | ---- | 28.21%850M | ---- | 40.07%423M | ---- | 8.51%663M | ---- | -17.26%302M |
Share of profit from joint venture company | ---- | -62.26%160M | ---- | -13.38%1.08B | ---- | -24.69%424M | ---- | 570.94%1.25B | ---- | 441.35%563M |
Special items of earning before tax | 93.52%-14M | -79.87%403M | 23.08%-60M | 48.12%3.82B | -61.19%-216M | 2.19%2B | -178.57%-78M | -38.16%2.58B | ---134M | 45.00%1.96B |
Earning before tax | 16.12%154.39B | 22.11%105.78B | 21.42%52.54B | -11.19%172.97B | -11.18%132.96B | -11.52%86.62B | -5.79%43.27B | 103.26%194.77B | 149.69B | 117.68%97.9B |
Tax | -6.81%-37.7B | -13.80%-26.03B | -14.79%-12.81B | 7.93%-48.88B | 13.78%-35.3B | 12.07%-22.87B | 4.01%-11.16B | -108.09%-53.09B | ---40.94B | -123.36%-26.02B |
After-tax profit from continuing operations | 19.48%116.68B | 25.09%79.75B | 23.72%39.73B | -12.41%124.09B | -10.21%97.66B | -11.32%63.75B | -6.39%32.11B | 101.51%141.68B | 108.76B | 115.70%71.88B |
Earning after tax | 19.48%116.68B | 25.09%79.75B | 23.72%39.73B | -12.41%124.09B | -10.21%97.66B | -11.32%63.75B | -6.39%32.11B | 101.51%141.68B | 108.76B | 115.70%71.88B |
Minority profit | 78.57%25M | 207.69%14M | 275.00%7M | 1,173.91%247M | 240.00%14M | -225.00%-13M | -300.00%-4M | -76.92%-23M | ---10M | -33.33%-4M |
Profit attributable to shareholders | 19.47%116.66B | 25.05%79.73B | 23.69%39.72B | -12.60%123.84B | -10.23%97.65B | -11.30%63.76B | -6.38%32.11B | 101.51%141.7B | 108.77B | 115.69%71.89B |
Basic earnings per share | 19.51%2.45 | 25.37%1.68 | 23.53%0.84 | -14.19%2.6 | -12.39%2.05 | -14.65%1.34 | -11.69%0.68 | 92.99%3.03 | 2.34 | 109.33%1.57 |
Diluted earnings per share | 19.51%2.45 | 25.37%1.68 | 23.53%0.84 | -14.19%2.6 | -12.39%2.05 | -14.65%1.34 | -11.69%0.68 | 92.99%3.03 | 2.34 | 109.33%1.57 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS and HKAS | CAS (2007) | IAS and HKAS | CAS (2007) | IAS and HKAS | CAS (2007) | IAS and HKAS | CAS (2007) | IAS and HKAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.